Combining SRS with ICIs has been clinically associated with improved local control and mOS in NSCLC patients with BM [8], and enhanced intracranial control has been observed in melanoma BM treated with CTLA-4 inhibitors plus SRS [9]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.